This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
by Zacks Equity Research
BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.
NVSPositive Net Change BMRNNegative Net Change BAYRYPositive Net Change ANIPNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
by Zacks Equity Research
Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
NVSPositive Net Change BAYRYPositive Net Change ANIPNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
by Zacks Equity Research
EXEL tops on earnings and sales in the third quarter as lead drug Cabometyx maintains momentum. The company also raises its revenue guidance for 2024.
ALNYPositive Net Change MRKPositive Net Change EXELNegative Net Change AMRNPositive Net Change
biotechnology biotechs earnings pharmaceuticals
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On CDXC's third-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its marketed product Niagen and updates on the pipeline.
BIIBPositive Net Change EXELNegative Net Change
biotechs
What to Expect From These 3 MedTech Stocks This Earnings Season
by Urmimala Biswas
Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.
BIONegative Net Change TECHNegative Net Change ZBHPositive Net Change
biotechs earnings medical medical-devices
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
BIIBPositive Net Change VRTXPositive Net Change EXELNegative Net Change CRSPPositive Net Change
biotechs
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.
NVSPositive Net Change LLYPositive Net Change INCYPositive Net Change FATEPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Gears Up to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in third-quarter 2024 in both the United States and International segments.
REGNPositive Net Change BIIBPositive Net Change NVOPositive Net Change ZTSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.
REGNPositive Net Change SNYPositive Net Change BIIBPositive Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?
by Ekta Bagri
BMY is looking to turnaround its business, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock, and we recommend it to investors.
BMYPositive Net Change PFEPositive Net Change
biotechnology biotechs earnings-preview pharmaceuticals
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs pharmaceuticals
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
COLL's Q3 performance is likely to have benefited from higher revenues from the sales of its pain-management drugs and the newly acquired neurology drug.
REGNPositive Net Change PFEPositive Net Change NVOPositive Net Change COLLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.
REGNPositive Net Change PFEPositive Net Change VRTXPositive Net Change CRSPPositive Net Change
biotechs cell-therapy crispr earnings gene-therapy medical pharmaceuticals
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.
BIIBPositive Net Change PFEPositive Net Change EXELNegative Net Change BNTXPositive Net Change
biotechs
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
by Zacks Equity Research
ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year. Shares down.
ALKSPositive Net Change FATEPositive Net Change CSTLPositive Net Change
biotechs earnings
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
FULC is expected to provide updates on its early-stage candidate for SCD, pociredir, in its third-quarter earnings release.
VRTXPositive Net Change CRSPPositive Net Change FULCPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.
RHHBYPositive Net Change JNJPositive Net Change NVOPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs earnings-preview earnings-surprise medical pharmaceuticals
Will New Drugs Help Biogen Surpass Q3 Earnings Estimates?
by Zacks Equity Research
In the third quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.
REGNPositive Net Change BIIBPositive Net Change PFEPositive Net Change
biotechs
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.
BIIBPositive Net Change GILDNegative Net Change EXELNegative Net Change CGENNegative Net Change
biotechs
Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
by Zacks Equity Research
FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.
MRKPositive Net Change TEVAPositive Net Change GILDNegative Net Change FOLDPositive Net Change EDITPositive Net Change
biotechnology biotechs pharmaceuticals
Precision BioSciences to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DTIL is expected to provide updates on its in vivo gene editing programs in the third-quarter earnings release, given the absence of a marketed product.
REGNPositive Net Change PFEPositive Net Change NVOPositive Net Change DTILNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?
by Zacks Equity Research
Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.
MRKPositive Net Change SMMTPositive Net Change TILNegative Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements
by Zacks Equity Research
Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.
FOLDPositive Net Change FATEPositive Net Change VKTXNegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
by Ekta Bagri
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
EXELNegative Net Change FOLDPositive Net Change CRSPPositive Net Change VRNANo Net Change
biotechnology biotechs crispr medical pharmaceuticals
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
REGNPositive Net Change BIIBPositive Net Change PFEPositive Net Change AMGNPositive Net Change
biotechs pharmaceuticals